Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with diagnosis of essential hypertension
Minimum age of 18 years

Exclusion criteria

Treatment and study plan

Telmisartan

Drug

Other names: Micardis®, low and high dose

Primary outcomes

Change in clinic blood pressure

Time frame: up to 14 days
Number of patients with adverse drug reactions

Time frame: up to 14 days

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Important dates

Study start: 2000
Primary completion: 2000
First posted: Sep 12, 2014
Registry last updated: Sep 12, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed